|1.||Tsutsui, Hidenobu: 2 articles (10/2013 - 01/2009)|
|2.||Takaoka, Masanori: 2 articles (10/2013 - 01/2009)|
|3.||Sugiura, Takahiro: 2 articles (10/2013 - 01/2009)|
|4.||Matsumura, Yasuo: 2 articles (10/2013 - 01/2009)|
|5.||Hayashi, Kentaro: 2 articles (10/2013 - 01/2009)|
|6.||Chung, H H: 2 articles (08/2013 - 09/2012)|
|7.||Mititelu-Tartau, Liliana: 1 article (01/2015)|
|8.||David, John M: 1 article (01/2015)|
|9.||Grigoraş, Ioana: 1 article (01/2015)|
|10.||Ma, Jeffrey C Y: 1 article (01/2015)|
10/15/2013 - "The suppressive effect of moxonidine on enhanced renal sympathetic nerve activity during renal ischemia was not observed in the rat treated with either i.v. (360 nmol/kg) or i.c.v. (36 nmol/kg) of efaroxan. "
10/15/2013 - "Furthermore, i.v. injection of efaroxan eliminated the preventive effect of moxonidine on ischemia/reperfusion-induced kidney injury and norepinephrine overflow, and i.c.v. injection of efaroxan did not completely inhibit the moxonidine's effects. "
01/28/2009 - "Pretreatment with efaroxan (30 mumol/kg, i.v.), an alpha(2)/I(1)-receptor antagonist, abolished the suppressive effects of agmatine on the enhanced renal sympathetic nerve activity during renal ischemia and on the elevated norepinephrine overflow after reperfusion, and eliminated the preventing effects of agmatine on the ischemia/reperfusion-induced renal dysfunction and histological damage. "
03/01/2001 - "Topical unilateral application of naphazoline (7.5, 25 and 75 micro g; 25 micro l) elicited an ipsilateral dose-dependent mydriasis (2, 4 and 5.5 mm) that peaked at 2 hr with a duration of up to 5 hr. The IOP decreases induced by naphazoline were bilateral and dose-dependent (3, 6 and 10 mmHg); the response peaked at 1 hr and lasted for up to 5 hr. Pretreatment with efaroxan (250 micro g) elicited significantly greater antagonism of the ocular hypotensive response to naphazoline than did rauwolscine (250 micro g) suggesting an involvement of imidazoline (I(1)) receptors. "
01/15/2005 - "Two antagonists (RS 79948 for alpha(2)-adrenoceptors and efaroxan for imidazoline I(1) receptors) were used to antagonize the mydriasis elicited by those three agonists, with antagonistic potencies calculated. "
01/01/2015 - "Selective α2-adrenergic blockade by efaroxan also increased primary tumor size and distant metastasis under non-stress conditions, but selective α1-adrenergic blockade by prazosin did not. "
05/01/2013 - "In this study we examined apoptotic activity of rilmenidine (potent I(1)-IR agonist), moxonidine (moderate I(1)-IR agonist), and efaroxan (I(1)-IR partial agonist) on cancer cell line (K562) expressing Nischarin. "
09/05/2005 - "However, alpha2-adrenoceptor agonists are known to induce hypothermia, therefore, the present study has investigated the ability of the selective alpha2-adrenoceptor antagonist, RX811059 (2-ethoxy idazoxan) and the mixed imidazoline1-binding site/alpha2-adrenoceptor antagonist, efaroxan, to attenuate the BU98008-induced hypothermia. "
07/01/2012 - "Pharmacological mechanism of the observed hypothermia was studied by combining the I(2) receptor agonists (2-BFI, BU224, tracizoline and diphenyzoline) with imidazoline I(2 ) receptor/ α(2) adrenoceptor antagonist idazoxan, selective I(1) receptor antagonist efaroxan, α(2) adrenoceptor antagonist/5-HT(1A) receptor agonist yohimbine. "
|5.||Acute Kidney Injury (Acute Renal Failure)
10/15/2013 - "In the present study, to clarify the renoprotective mechanisms of moxonidine (360 nmol/kg, i.v.) against ischemic acute kidney injury, we investigated the effect of intravenous (i.v.) and intracerebroventricular (i.c.v.) injection of efaroxan, an α2/Ι1 receptor antagonist, on the moxonidine-exhibited actions. "
|4.||Naphazoline (Clear, All)
|7.||Acetic Acid (Vinegar)
|9.||Serotonin (5 Hydroxytryptamine)